Investigational drug · Phase 3
Nemtabrutinib
Also called: MK-1026, ARQ 531
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
26
Any phase or sponsor naming "Nemtabrutinib"
First trial start
2017
Jun 26, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nemtabrutinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Richter Transformation Lymphoma
- Hematologic Malignancies
- Waldenstroms Macroglobulinaemia
- Non-Hodgkins Lymphoma
- Chronic Lymphocytic Leukaemia
- Leukemia, Lymphocytic, Chronic, B-Cell
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Nemtabrutinib" as an intervention, largest first.
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136559 · 1,200 participants (planned) · Start Dec 13, 2023 · Primary completion Sep 7, 2032
Drug: Nemtabrutinib; Ibrutinib and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 206 sites in all
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05947851 · 735 participants (planned) · Start Aug 8, 2023 · Primary completion Jun 1, 2032
Drug: Nemtabrutinib; Venetoclax and 1 more · For: Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma and 3 more
Sites: Springdale, Arkansas; Long Beach, California; Clermont, Florida · 107 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04728893 · 490 participants (planned) · Start Apr 5, 2021 · Primary completion Jan 4, 2029
Drug: Nemtabrutinib · For: Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma and 1 more
Sites: Springdale, Arkansas; La Jolla, California; Torrance, California · 121 sites in all
- A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05624554 · 300 participants (planned) · Start Mar 16, 2023 · Primary completion May 19, 2027
Drug: Nemtabrutinib; Fludarabine and 6 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Springdale, Arkansas; Clermont, Florida; Hattiesburg, Mississippi · 97 sites in all
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruiting
NCT03162536 · 190 participants (planned) · Start Jun 26, 2017 · Primary completion Sep 17, 2027
Drug: Nemtabrutinib · For: Lymphoma, B-Cell; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia and 6 more
Sites: Scottsdale, Arizona; Los Angeles, California; Denver, Colorado · 10 sites in all
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05458297 · 189 participants (planned) · Start Jul 21, 2022 · Primary completion May 17, 2029
Drug: Zilovertamab vedotin; Nemtabrutinib · For: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma and 1 more
Sites: Anchorage, Alaska; Gilbert, Arizona; Phoenix, Arizona · 109 sites in all
- A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)Completed
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06586671 · 40 participants · Start Aug 28, 2023 · Primary completion Nov 13, 2023
Drug: Nemtabrutinib · For: Hematological Malignancy
Sites: South Miami, Florida
City of Hope Medical CenterAcademic, hospital or other
NCT07583810 · 35 participants (planned) · Start Oct 23, 2026 · Primary completion Sep 25, 2030
Drug: Nemtabrutinib; Rituximab · For: Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma; Gastric Mucosa-Associated Lymphoid Tissue Lymphoma; Marginal Zone Lymphoma and 4 more
Sites: Duarte, California
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT07796373 · 32 participants (planned) · Start Nov 24, 2026 · Primary completion Dec 1, 2030
Drug: Nemtabrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
Sites: Bethesda, Maryland
Roswell Park Cancer InstituteAcademic, hospital or other
NCT06863402 · 32 participants (planned) · Start Nov 15, 2026 · Primary completion Jun 1, 2029
Drug: Nemtabrutinib; Pembrolizumab · For: Richter Syndrome; Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia
Sites: Buffalo, New York
Newest research
PubMed records naming it or its code names, newest first.
- Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutation.
Omer Z, Rogers KA, Yano M, et al. · Blood Adv 2026
- From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.
Robak T · Expert Opin Pharmacother 2026
- Computational hybrid framework integrating clinical-mutation profiling and physics-based simulations to predict structural tolerance of Bruton tyrosine kinase (BTK) and sustained ARQ 531 binding.
Khan A, Sawali MA, Shkoor M, et al. · Curr Res Struct Biol 2026
- Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies.
Kemal CC, Zweers TJ, Krekels EHJ, et al. · CPT Pharmacometrics Syst Pharmacol 2026
- The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.
Robak T, Iskierka-Jażdżewska E, Pua A, et al. · J Clin Med 2025
- Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers.
Kluitmans DJF, Melis JJTM, van den Bossche E, et al. · Front Oncol 2025
Also in development for Chronic Lymphocytic Leukemia
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- NX-5948bexobrutidegPhase 33 trials
Nurix Therapeutics, Inc. · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials
Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
- EmavusertibCA-4948Phase 22 trials
Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.